Clinical Trial: Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients

Brief Summary: The objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and maintain the AT activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac surgery.

Detailed Summary:
Sponsor: Mayo Clinic

Current Primary Outcome: Percentage of time within the serum AT level target range of 80-100% [ Time Frame: 72 hour infusion period ]

Target value of Antithrombin is recorded as %


Original Primary Outcome: Percentage of time within the serum AT level target range of 80-100% [ Time Frame: 72 hour infusion period ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Mayo Clinic

Dates:
Date Received: March 21, 2017
Date Started: July 1, 2017
Date Completion: October 2017
Last Updated: April 12, 2017
Last Verified: April 2017